Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27209670 | 0.85 | ALDH1A1 (0.41) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL27233676 | 0.84 | FAAH (0.45) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL5943052 | 0.83 | MAPK1 (0.44) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL1013370 | 0.82 | KDM4E (0.44) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL27233695 | 0.82 | MAPK1 (0.43) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL30657584 | 0.82 | KDM4E (0.44) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL1013138 | 0.82 | MEN1 (0.40) | ALDH1A1MEN1KMT2AMAOBCYP1A2 | |
| SCHEMBL25294746 | 0.80 | CYP1A2 (0.54) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL29479474 | 0.80 | CYP1A2 (0.54) | ALDH1A1KDM4EMEN1BRCA1HBB | |
| SCHEMBL27209648 | 0.80 | PGK1 (0.40) | ALDH1A1KDM4EMEN1BRCA1HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NEUROPN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | ASTRIZI BIO, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | NeuroPn Therapeutics, Inc. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073648-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073680-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110060012-A1 | 4-[3-(ARYLOXY)BENZYLIDENE]-3-METHYL PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110053949-A1 | 4-[3-(ARYLOXY)BENZYLIDENE]-3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2276737-A1 | 4- [3- (ARYLOXY) BENZYLIDENE]-3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2276736-A1 | 4- [3- (ARYLOXY) BENZYLIDEN]-3-METHYL PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009127949-A1 | 4- [3- (ARYLOXY) BENZYLIDENE] -3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127948-A1 | 4- [3- (ARYLOXY) BENZYLIDENE] -3-METHYL PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | CHEK1, CHEK2, BUB3 | ALDH1A1 363/4885KDM4E 1146/4885MEN1 4414/4885 |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | PDCD1, TP53, CHEK2 | ALDH1A1 564/4885KDM4E 460/4885MEN1 4395/4885 |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | GLP1R, GIPR, GPR119 | ALDH1A1 1688/4885KDM4E 942/4885MEN1 4230/4885 |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PARK7, FAAH | ALDH1A1 201/4885KDM4E 2910/4885MEN1 4856/4885 |
| US-20110060012-A1 | 4-[3-(ARYLOXY)BENZYLIDENE]-3-METHYL PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, CNR2 | ALDH1A1 433/4885KDM4E 413/4885MEN1 4422/4885 |
| US-20110053949-A1 | 4-[3-(ARYLOXY)BENZYLIDENE]-3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, CNR2 | ALDH1A1 490/4885KDM4E 428/4885MEN1 4426/4885 |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | ALDH1A1 360/4885KDM4E 1643/4885MEN1 4102/4885 |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRPH, EPHX1, BCHE | ALDH1A1 423/4885KDM4E 382/4885MEN1 4843/4885 |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, HPGDS | ALDH1A1 241/4885KDM4E 454/4885MEN1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.